ResMed revenue and financials
$220.69Change from previous close: −0.97%Absolute change: −$2.17
In the fiscal year ended June 2026, ResMed reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.
Fiscal year ending in June. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +9.85%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +8.75%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 26.9%
- FY to Jun 2025: 27.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Jun 2026 | FY to Jun 2025 | FY to Jun 2024 | FY to Jun 2023 | FY to Jun 2022 | FY to Jun 2021 | FY to Jun 2020 | FY to Jun 2019 | FY to Jun 2018 | FY to Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,806 | 1,752 | 1,401 | 693 | 351 | 737 | 802 | 459 | 505 | 414 |
| Depreciation and amortization | 201 | 198 | 177 | 165 | 160 | 157 | 155 | 151 | 120 | 112 |
| Capital expenditure | -156 | -89.9 | -99.5 | -120 | -135 | -103 | -95.3 | -68.7 | -62.6 | -62.2 |
| Investing cash flow | -545 | -200 | -270 | -1,160 | -230 | — | — | — | — | — |
| Financing cash flow | -1,007 | -606 | -1,119 | 423 | -128 | — | — | — | — | — |
| Dividends paid | -350 | -311 | -282 | -258 | -245 | -227 | -225 | -212 | -199 | -186 |
| Share repurchases | -700 | -300 | -150 | 0.0 | 0.0 | — | — | -22.8 | -53.8 | — |
| Debt issued | 0.0 | 0.0 | 105 | 1,070 | — | — | — | — | — | — |
| Debt repaid | -10.0 | -40.0 | -835 | -405 | — | — | — | — | — | — |
| Effect of exchange rates | 6.2 | 25.8 | -1.7 | -2.1 | -14.4 | — | — | — | — | — |
| Net change in cash | 260 | 971 | 10.5 | -45.8 | -21.6 | — | — | — | — | — |
| Free cash flow | 1,650 | 1,662 | 1,302 | 574 | 216 | — | — | — | — | — |
| Levered free cash flow | 939 | 1,208 | 1,185 | 401 | 128 | — | — | — | — | — |